

14 Open Doctoral Positions – ENTRY-DM European Union Funded MSCA Doctoral Network

Advancing Therapeutic Development for Myotonic Dystrophy

Rare diseases, like Myotonic Dystrophy (DM), affect tens of thousands in Europe and present significant challenges in diagnosis, treatment, and clinical trials. ENTRY-DM offers 14 doctoral full-time positions across Europe to advance antisense oligonucleotide (ASO) therapies for DM by innovative and collaborative research.

About the ENTRY-DM Network

ENTRY-DM combines international experts in DM research, bioengineering, ASO chemistry, and clinical trials. Through collaborations with multi-sectoral partners, we are tackling technology transfer challenges and preparing doctoral candidates (DC) to make significant contributions in ASO therapeutic development.

Why Join?

- Interdisciplinary training in disease mechanisms, ASO design, drug delivery, and clinical trials
- Hands-on experience with bioengineering, clinical assessments, and neuropsychological evaluations
- Collaborate with industry leaders and top international researchers, through international mobility
- Access to state-of-the-art labs, cutting-edge research and top-level training events by world experts
- Prepare for a successful career in clinical trials and therapeutic development in academia and industry

Candidates from all nationalities with a strong fundamental or clinical background in biomedical sciences, bioengineering, or related fields are encouraged to apply. Application deadline May 30, 2025.

Please ensure that you comply with EU eligibility and mobility conditions before applying.

Ready to make an impact in rare disease research? Apply now at the links below!

DC1 Innovative genomic technologies for the advanced characterization of myotonic dystrophy mutations (Genartis • Verona, Italy)

https://euraxess.ec.europa.eu/jobs/324011

DC2 The complexity of DM repeat expansions: new challenges in developing personalised molecular therapeutics (UTOV • Rome, Italy)

https://euraxess.ec.europa.eu/iobs/324039

DC3 A new integrated in vitro platform to study DM muscle disease (IBEC • Barcelona, Spain) https://euraxess.ec.europa.eu/jobs/324043

DC4 Advanced human 3D neuromuscular and cortical models for mechanistic and therapeutic research (CECS • Paris, France)

https://euraxess.ec.europa.eu/jobs/324049

DC5 Structure and dynamics of nuclear RNA foci in myotonic dystrophy type 1 and 2 (RUMC • Nijmegen, The Netherlands)

https://euraxess.ec.europa.eu/jobs/324052

DC6 The contribution of miRNome alterations to DM1: beyond the Muscleblind sequestration model (UVEG • Valencia, Spain)

https://euraxess.ec.europa.eu/iobs/324056

DC7 Rescuing disrupted single-cell and neural network activities in human DM neural models using ASO (RUMC • Nijmegen, The Netherlands)

https://euraxess.ec.europa.eu/jobs/324077

DC8 Therapeutical potential of ASO inducing skipping of CUGexp-containing exon in myotonic dystrophy (AMU • Poznan, Poland)

https://euraxess.ec.europa.eu/jobs/324410

DC9 Enhancing the activity of therapeutic ASO by genetic modulation and sequence motif adjuvants (UVEG • Valencia, Spain)

https://euraxess.ec.europa.eu/jobs/324418

DC10 Novel ASO molecules for the therapy of DM1 (CSIC • Barcelona, Spain)

https://euraxess.ec.europa.eu/jobs/324425

DC11 Development of circulating muscle-specific biomarkers of myotonic dystrophy (Inserm • Paris, France)

https://euraxess.ec.europa.eu/jobs/324426

DC12 Circulating biomarkers of brain dysfunction in myotonic dystrophy type 1 (Inserm • Paris, France) https://euraxess.ec.europa.eu/jobs/324434

DC13 Myotonic Dystrophy Type 2 (DM2): Biomarker discovery and correlation to clinical outcomes (LMU • Munich, Germany)

https://euraxess.ec.europa.eu/jobs/324437

DC14 Participation in clinical trials: the contribution of decision-making cognition in patients with DM1 (UPC • Paris, France)

https://euraxess.ec.europa.eu/jobs/324450

Eligibility criteria Application procedure







